Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study

OBJECTIVE: This study aimed to determine the efficacy and tolerability of apatinib plus dose-dense temozolomide (TMZ) as first-line treatment for recurrent glioblastoma (rGBM). METHODS: Patients with rGBM were enrolled in this study. Patients were subjected to concurrent treatment of apatinib (500 m...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Onco Targets Ther
Main Authors: Wang, Yong, Meng, Xiangji, Zhou, Shizhen, Zhu, Yufang, Xu, Jun, Tao, Rongjie
Format: Artigo
Sprog:Inglês
Udgivet: Dove 2019
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6899067/
https://ncbi.nlm.nih.gov/pubmed/31819537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S226804
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker